Meeting overview outlines global pharmacovigilance frameworks in international healthcare sectors, highlighting collaborative strategies to advance medication safety and drug monitoring.
This 25 th edition marks a key milestone as the Annual Meeting becomes the ISoP Global Meeting driven by strong growth in membership and regional events.This expansion strengthens ISoP's global influence and underscores the community's active engagement in pharmacovigilance worldwide.The conference, featuring over 26 scientific sessions, offers an extensive programme including four pre-conference courses, plenary sessions, and multiple parallel sessions addressing key pharmacovigilance themes such as safety in special populations, digital transformation and AI, evidence generation, risk management, regulatory science, and ethics.For the first time, ISoP members have suggested workshop and sessions, and this will raise new ideas for discussion.A distinguished panel of international experts from regulatory authorities, academia, industry, clinical practice and patient organisations will share cutting-edge knowledge and real-world experience on medication errors, medical devices, vaccines and public health, wider pharmacovigilance horizons, regional advances, and both patient and professional development.Together with the ISoP LATAM chapter and in synergy with the WHO Programme for International Drug Monitoring meeting that will follow in San Jose ´, ISoP 2026 is a unique platform to co-create ''ecosystems of trust'' that strengthen pharmacovigilance for a healthier world.The WHO-ISoP Joint Meeting 2026 will showcase the longstanding collaboration between the World Health Organization (WHO) and the International Society of Pharmacovigilance (ISoP), highlighting their shared commitment to advancing pharmacovigilance science, education, and practice worldwide.Under the theme ''WHO-ISoP PV Curriculum: Supporting Smart Pharmacovigilance,'' the session will mark the launch of the revised WHO-ISoP Pharmacovigilance Curriculum 2026.Discussions will also explore how the curriculum can support capacity building, professional development, and stronger pharmacovigilance systems worldwide.As always, ISoP continues to foster learning, collaboration, and innovation across all continents.Whether you're a regulator, healthcare professional, academic, industry representative, or student-your role in advancing medication safety is vital, and your presence here enriches our collective mission.We are delighted to welcome you to Costa Rica and hope this meeting inspires renewed commitment, shared learning, and new connections.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: